By Skyepharma Production…
To get in touch with Skyepharma Production S.A.S., simply fill out the form below.
Subscribe to Supplier
Development partner Skyepharma bringing modified release advances to virtual BIO-Europe Digital
Saint-Quentin-Fallavier, France: – Skyepharma Productions S.A.S. (Skyepharma), the French-based fully-formed contract development and manufacturing organisation, will have a prominent online presence at the BIO Europe DIGITAL virtual networking and partnering event later this month.
This maintains Skyepharma’s close relationship with the BIO series, having attended previous BIO-Europe events over the past three years, most recently BIO Spring and BIO US Digital this year.
Partner for Development
Once again, the Skyepharma team will be looking to forge new relationships as a Partner for Development with organisations looking for collaboration and support in R&D, formulation development and Life Cycle Management for solid dosage forms.
In line with its core business mission to offer expertise and technologies that support partners to design and improve their products with the most appropriate formulation and release profile, Skyepharma will be highlighting its three technologies for modified controlled drug release:
- Geomatrix®: multi-layer tablet for sustained and controlled release
- Geoclock® tab-in-tab for delayed release
- Soctec®: enteric capsule for extended release
Modified release benefits
“These modified release (MR) oral formats deliver impressive client benefits in improving the action of molecules and drug products by allowing more precisely targeted delivery, making possible new indications, reducing drug intake and side effects, and improving overall patient comfort and compliance,” commented Skyepharma Pharmaceutical Development Director Dr. Aline Moulin, who will be a prominent member of the team at BIO-Europe Digital, along with Pharmaceutical Project Manager Dr. Vanessa Bourgeaux, and Operations Director Dr. Frederic Checot.
In a recent publication on ONdrugDelivery magazine, Dr. Aline Moulin and Dr. Mathieu Degomme shared case study insights illustrating these benefits (see Resources).
“Using the impressive online partnering platforms set up for BIO-Europe Digital, we will be looking to connect with small, medium-sized and big pharma, including biotechs and research consultants, looking to add value to their product portfolio without compromising quality of products and time to market,’ commented Dr. Checot.
“We can support them with our R&D capabilities and expertise in modified release, supported by deep experience in formulation development, and proven efficiency in solving complex formulation development challenges,” he continued.
About Skyepharma Production
Skyepharma Production S.A.S. (Skyepharma) is a key player in drug development and delivery of oral technologies serving the global pharmaceutical, biotech and consumer health industries.
Skyepharma is the oral business unit of the Vectura Group of companies, an international leader in inhalation and other drug delivery forms.
The company’s vision is to help solve healthcare industry complexity with a mission to provide a dedicated and results-oriented team to deliver advanced oral dosage services to the healthcare industry through state-of-the-art facilities, scientific expertise and open, transparent relationships.
Skyepharma offer in solid oral dosage formats encompasses the whole value chain, including Formulation Development & Process Design, Analytical Development, Scale-up, Manufacturing, Packaging, Serialisation and Aggregation.
Skyepharma also provides a range of support services that help client companies from early stage development (up to phase III), through scale-up and full commercial manufacturing and packaging to market introduction, including controlled substance handling, QbD methodology (FMEA, FTA, DOE), Troubleshooting, regulatory services, validation, registration and warehousing services.
More at: https://www.skyepharma.fr.
About BIO Europe DIGITAL 2020
The biannual BIO-Europe events are premier partnering conferences dedicated to driving forward partnering in the life sciences sector. They attract an international “who’s who” from biotech, pharma and finance for high caliber networking.
As with BIO-Europe Spring earlier this year, the originally scheduled four-day physical event has been repurposed as a COVID-19 friendly digital online edition, using forums, webinars and video conferencing technology to allow the same networking and knowledge sharing benefits as the ‘live’ event, along with the sophisticated partneringONE® platform to enable networking and meetings between financiers, innovators and companies across the life science value chain, from large biotech to start-ups.
BIO Europe will remain a four-day event, opening October 26, that will provide intensive networking for biotechnology and pharma leaders to discover new opportunities and promising partnerships. The event will feature more than 40 presentations spread across five streams, including Biotech Ecosystem, Business Development, Microbiome Therapeutics and Therapeutic applications.
BIO Europe DIGITAL is organised by the EBD Group in association with the Washington DC-based Biotechnology Innovation Organisation. Further information at: https://informaconnect.com/bioeurope/.
Click on Recent development in complex tablet formulations to see Skyepharma article posted on LinkedIn.
Click on Controlled Release Technologies for more on Skyepharma modified release formulations.
Click on Skyepharma Pharmaceutical Development Services to watch video.
Click on SkyePharma Events to watch videos and see latest events updates.